These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28984786)

  • 41. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ki-67 Labeling Index Variability Between Surgically Resected Primary and Metastatic Hepatic Lesions of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Furukawa T; Ozaka M; Takamatsu M; Takazawa Y; Inamura K; Inoue Y; Mie T; Takeda T; Kanata R; Kasuga A; Matsuyama M; Sasaki T; Takahashi Y; Sasahira N
    Int J Surg Pathol; 2021 Aug; 29(5):475-481. PubMed ID: 33543658
    [No Abstract]   [Full Text] [Related]  

  • 43. [Accurate grading of pancreatic neuroendocrine tumors with Ki-67 index in fine-needle aspiration specimens: a comparative cytologic and histologic study].
    He SR; Cui D; Gong H; Zhu YP; Chen L; Hu ST; Liu DG
    Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):393-399. PubMed ID: 28591986
    [No Abstract]   [Full Text] [Related]  

  • 44. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.
    Larghi A; Capurso G; Carnuccio A; Ricci R; Alfieri S; Galasso D; Lugli F; Bianchi A; Panzuto F; De Marinis L; Falconi M; Delle Fave G; Doglietto GB; Costamagna G; Rindi G
    Gastrointest Endosc; 2012 Sep; 76(3):570-7. PubMed ID: 22898415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior.
    Díaz Del Arco C; Esteban López-Jamar JM; Ortega Medina L; Díaz Pérez JÁ; Fernández Aceñero MJ
    Diagn Cytopathol; 2017 Jan; 45(1):29-35. PubMed ID: 27863178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Grade 2 pancreatic neuroendocrine tumors: overbroad scope of Ki-67 index according to MRI features.
    Hu Y; Rao S; Xu X; Tang Y; Zeng M
    Abdom Radiol (NY); 2018 Nov; 43(11):3016-3024. PubMed ID: 29619528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms.
    Khan MS; Luong TV; Watkins J; Toumpanakis C; Caplin ME; Meyer T
    Br J Cancer; 2013 May; 108(9):1838-45. PubMed ID: 23579216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
    Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Automated quantification of Ki-67 index associates with pathologic grade of pulmonary neuroendocrine tumors.
    Wang HY; Li ZW; Sun W; Yang X; Zhou LX; Huang XZ; Jia L; Lin DM
    Chin Med J (Engl); 2019 Mar; 132(5):551-561. PubMed ID: 30807354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
    Strosberg J; Nasir A; Coppola D; Wick M; Kvols L
    Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can the Ki-67 Labeling Index in Biopsy Specimens Predict the World Health Organization Grade of Rectal Neuroendocrine Tumors?
    Sugimoto S; Hotta K; Shimoda T; Imai K; Ito S; Yamaguchi Y; Takizawa K; Kakushima N; Tanaka M; Kawata N; Yoshida M; Ishiwatari H; Matsubayashi H; Ono H
    Dig Dis; 2018; 36(2):118-122. PubMed ID: 29130971
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.
    Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?
    Grillo F; Valle L; Ferone D; Albertelli M; Brisigotti MP; Cittadini G; Vanoli A; Fiocca R; Mastracci L
    Endocrine; 2017 Sep; 57(3):494-502. PubMed ID: 28726181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
    Delektorskaya VV; Kozlov NA; Chemeris GY
    Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors.
    Dhall D; Mertens R; Bresee C; Parakh R; Wang HL; Li M; Dhall G; Colquhoun SD; Ines D; Chung F; Yu R; Nissen NN; Wolin E
    Hum Pathol; 2012 Apr; 43(4):489-95. PubMed ID: 21937080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors.
    Goodell PP; Krasinskas AM; Davison JM; Hartman DJ
    Am J Clin Pathol; 2012 Apr; 137(4):576-82. PubMed ID: 22431534
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
    Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
    J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
    Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
    Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.